Contact us online
or at 913.451.3955.
Case studies
More information
505(b)(2) NDA and MAA for Orally Disintegrating Tablet
105 Kb – PDF CMC and Global Regulatory Support for Generic Tablet
130 Kb – PDF Complete Response Letter Resolution and NDA Amendment
167 Kb – PDF Design of API Manufacturing Facility
100 Kb – PDF Global Drug Development Strategy and Special Protocol Assessments
155 Kb – PDF Global Regulatory Support for IV and IM Formulations
144 Kb – PDF PAI Audit in China
111 Kb – PDF
